Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 39,281 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

39,281 Papers indexed
1,440 Papers AI scored
39,281 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

39281 results
B
AI -
Standard 79.74
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 66.2; sample size: 40.0; recency: 90.0; abstract quality: 100.0.

B
AI -
Standard 79.72
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 58.6; sample size: 60.0; recency: 100.0; abstract quality: 85.0.

B
AI -
Standard 79.7
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 51.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.

B
Anlotinib plus toripalimab in patients with advanced bone and soft tissue sarcomas including ultra-rare sarcomas: A multicenter, single-arm, phase 2 trial.
PMID 42258994 Published: 2026-06-06 Ingested: 2026-08-02 12:07 AM European journal of cancer (Oxford, England : 1990)
AI -
Standard 79.7
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 51.0; sample size: 40.0; recency: 100.0; abstract quality: 85.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 23.5; sample size: 80.0; recency: 100.0; abstract quality: 100.0.

B
Effects of PM2.5 Reduction Interventions on Cardiovascular Indicators: A Meta-analysis.
PMID 41057567 Published: 2025-10-07 Ingested: 2026-08-02 12:05 AM Cardiovascular toxicology
AI -
Standard 79.7
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 28.5; sample size: 90.0; recency: 100.0; abstract quality: 100.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 80.0; human relevance: 95.0; therapeutic relevance: 53.5; sample size: 60.0; recency: 100.0; abstract quality: 100.0.

B
Population Pharmacokinetics Modeling of Selpercatinib to Support Posology in Pediatric Patients With RET-Altered Metastatic Thyroid Cancer or Solid Tumors.
PMID 40358020 Published: 2025-05-13 Ingested: 2026-08-02 12:12 AM CPT: pharmacometrics & systems pharmacology
AI -
Standard 79.7
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 36.0; sample size: 80.0; recency: 90.0; abstract quality: 85.0.

B
Application of Neoadjuvant Docetaxel plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial.
PMID 40260648 Published: 2025-07-01 Ingested: 2026-08-02 12:04 AM Clinical cancer research : an official journal of the American Association for Cancer Research
AI -
Standard 79.7
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 46.0; sample size: 60.0; recency: 90.0; abstract quality: 85.0.

B
The effect of lamotrigine on cortical inhibition and plasticity in Neurofibromatosis type 1: Exploratory analysis of a randomized controlled trial (NF1-EXCEL).
PMID 40121838 Published: 2025-03-10 Ingested: 2026-08-02 12:04 AM Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
AI -
Standard 79.7
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 51.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

B
Interventions on Fruit and Vegetable Intake in Low-, Middle-, and High-Income Countries: A Scoping Review of Evidence and Knowledge Gaps.
PMID 40033515 Published: 2025-03-03 Ingested: 2026-08-02 12:03 AM Food and nutrition bulletin
AI -
Standard 79.7
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 23.5; sample size: 60.0; recency: 90.0; abstract quality: 100.0.

Previous
Page 241 of 3274
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic